Shots:

• The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda- characterizing PK/PD profile and to determine the recommended dose of the combination regimen
• The study is divided into two parts into Part A- a dose escalation of BI-1206 in combination with the standard dose of Keytruda- and part B- which will explore the activity of the combination regimen in patients with advanced lung cancer- melanoma and other types of malignancies
• The study will be conducted at multiple sites across the US & EU and will assess its antitumoral activity- as well as explore the expression of potential immunological markers that might predict clinical responses. BI-1206 is a mAb targeting FcgRIIb- currently being evaluated in patients with NHL

Click here to read full press release/ article | Ref: BioInvent | Image: Merck